MBMakoto Bonkobara

Makoto Bonkobara

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Makoto Bonkobara has a total of 177 co-authors. Here are the top co-authors by number of shared publications:

  • Kyoichi Tamura

    Laboratory of Veterinary Clinical Pathology, Nippon Veterinary and Life Science University, Tokyo, Japan

    15 shared publications
  • Ryo Miyamoto

    Laboratory of Veterinary Small Animal Internal Medicine, Iwate University, Morioka, Japan

    11 shared publications
  • Hiroyuki Tani

    Department of Veterinary Clinical Pathology, Nippon Veterinary and Life Science University, Tokyo, Japan

    10 shared publications
  • Kazuhiko Ochiai

    School of Veterinary Nursing and Technology, Faculty of Veterinary Science, Nippon Veterinary and Life Science University, Tokyo 180-8602, Japan

    10 shared publications
  • Tsukimi Washizu

    Department of Veterinary Clinical Pathology Nippon Veterinary and Life Science University Kyonan‐cho Musashino‐shi Tokyo Japan

    8 shared publications
  • Kenichiro Ono

    Japan Animal Referral Medical Center

    7 shared publications

Latest Publications

  • Open Access

    Dual inhibition of PLK1 and CDK1/2 selectively suppresses the growth of canine squamous cell carcinoma cell lines with truncating TP53 mutations

    by Ryo Miyamoto, Kyoichi Tamura, Makoto Bonkobara

    Background: Canine squamous cell carcinoma (SCC) remains a clinically challenging malignancy with limited therapeutic options for advanced or non-resectable cases. In this study, canine SCC cell lines harboring truncating TP53 mutations were identified, and TP53-associated therapeutic vulnerabilities were investigated. Results: Genetic analysis of TP53 in five canine SCC cell lines revealed premature termination codon–generating mutations in two lines: c.207_208insC (p.Thr70Hisfs*82) and c.234_235delinsA (p.Trp78*). TP53 protein could not be detected in western blot analysis of cell lines carrying these mutations. Although treatment with polo-like kinase 1 (PLK1) inhibitors alone (volasertib, BI2536, or GSK461364) did not induce selective growth inhibition, combined treatment with volasertib and the cyclin-dependent kinase (CDK)1/2 inhibitor BMS-265246 resulted in selective and synergistic growth suppression in TP53 -mutant cell lines. Conclusions: PLK1 and CDK1/2 cooperatively regulate G2/M progression via interconnected signaling pathways negatively regulated by TP53. Loss of TP53 may therefore increase cellular dependence on PLK1-CDK1/2 signaling, providing a potential mechanistic basis for the observed selective sensitivity to dual inhibition. These findings highlight the potential for exploiting TP53 loss–associated vulnerabilities in canine SCC and suggest further investigation into PLK1-CDK1/2 co-targeting strategies is warranted.

  • Open Access

    Molecular Characterization of Hotspot Mutations in HER2, BRAF, KRAS, and PIK3CA in Canine Pulmonary Adenocarcinoma from Japan

    by Asumi Muramatsu, Tomokazu Nagashima, Kazuhiko Ochiai, Amo Ohnuma, Honoka Kawamura, Yukino Machida, Daigo Azakami, Makoto Bonkobara, Toshiyuki Ishiwata, Masaki Michishita

    Primary pulmonary adenocarcinoma in dogs is rare, and effective systemic therapies remain limited. To evaluate the molecular basis of potential precision oncology approaches, hotspot mutations in HER2, BRAF, KRAS, and PIK3CA were analyzed in 20 surgically resected canine pulmonary adenocarcinomas and three canine pulmonary adenocarcinoma cell lines. HER2 V659E and BRAF V595E mutations were each detected in 3/20 cases (15%), while KRAS G12V was detected in 1/20 cases (5%). No PIK3CA hotspot mutations were identified. The BRAF V595E mutation was additionally detected in the AZACL2 cell line. Functional analysis demonstrated increased sensitivity of AZACL2 cells to the BRAF inhibitor dabrafenib and MEK inhibitors including trametinib, compared with BRAF wild-type cell lines. These findings support MAPK pathway dependency in BRAF-mutant canine pulmonary adenocarcinoma. The mutation spectrum was broadly consistent with previous reports, suggesting a conserved molecular landscape across geographic regions. Collectively, these data identify BRAF and HER2 alterations as clinically relevant candidates for molecular diagnostics and targeted therapy in canine pulmonary adenocarcinoma.

  • Open Access

    Antitumor Effect of mTOR1/2 Dual Inhibitor AZD8055 in Canine Pulmonary Carcinoma

    by Tomokazu Nagashima, Kazuhiko Ochiai, Yuka Takizawa, Youta Koike, Takahiro Saito, Asumi Muramatsu, Daigo Azakami, Yukino Machida, Makoto Bonkobara, Toshiyuki Ishiwata, et al.

    Background/Objectives: Primary pulmonary carcinoma (PC) is a malignant neoplasm that occurs in humans, dogs, and other species. In canine PC, palliative care remains the most practical approach for dogs with inoperable PC. Methods: We investigated the effectiveness of mammalian target of rapamycin (mTOR) inhibitors in canine lung cancer upon PI3K/AKT/mTOR activation. Three canine PC cell lines (AZACL1, AZACL2, and cPAC-1) were treated with three mTOR inhibitors (AZD8055, temsirolimus, and everolimus). In vitro, sensitivity assays were conducted to evaluate proliferation and Western blotting was used to examine pathway activation and phosphorylation of mTOR-related protein. Results: AZD8055 had a stronger inhibitory effect on cell proliferation than temsirolimus and everolimus in all three PC cell lines. The IC50 for AZD8055 in the AZACL1, AZACL2, and cPAC-1 cell lines were 23.8 μM, 95.8 nM, and 237 nM, for temsirolimus they were 34.6 μM, 11.5 μM, and 11.2 μM, and for everolims they were 36.6 μM, 33.4 μM, and 33.0 μM, respectively. Western blotting revealed PI3K/AKT/mTOR pathway activation and differential phosphorylation of mTOR signal-related proteins across the three PC cell lines. In xenograft mice injected with the AZACL1 and AZACL2 cell lines we showed that the AZD8055-treated group exhibited a significant reduction in tumor volume via the inhibition of tumor growth compared to the control group. Conclusions: These findings reveal that the PI3K/AKT/mTOR pathway plays a key role in canine PC and that AZD8055 may be a novel therapeutic agent for PC-bearing dogs.


  • Open Access

    Molecular Classification Based on the Gene Expression Profiles in Canine Histiocytic Sarcoma Cells

    by Hiroki Sakuma, Hirotaka Tomiyasu, Akiyoshi Tani, Yuko Goto‐Koshino, Makoto Bonkobara, Masaru Okuda

    The molecular abnormalities of canine histiocytic sarcoma (CHS) remain to be elucidated. We previously revealed that the sensitivities to dasatinib and trametinib were significantly various among CHS cell lines, indicating the differences in underlying molecular abnormalities. In the present study, we performed RNA sequencing analysis using 11 CHS cell lines to investigate molecular classifications based on the gene expression profiles (GEPs). The clustering analysis showed that CHS cell lines were divided into two distinct clusters. The comparisons of GEPs between the clusters extracted 675 differentially expressed genes (DEGs), and these DEGs were enriched with those related to the regulations of inflammatory responses. Among these DEGs, differences in the expressions of CCL3, CCL4, CCL7, CLEC7A, and TLR4 genes between the two groups were confirmed by RT‐qPCR. Since no significant difference in the activation status of Akt and ERK pathways was observed between the two groups, the NF‐κB pathway was focused on and its activation status was examined in the cell lines. As a result, cell lines belonging to one cluster showed nuclear translocation of the p65 protein together with increased release of CCL5 protein, which is a target molecule of the NF‐κB pathway, in a cell culture supernatant. These results suggested that the molecular pathology of CHS cells might be divided into two categories depending on the activation status of the NF‐κB pathway, and it is necessary to establish precision medicine for each molecular subtype of CHS.


  • Open Access

    A Canine c-kit Novel Mutation Isolated from a Gastrointestinal Stromal Tumor (GIST) Retains the Ability to Form Dimers but Lacks Autophosphorylation

    by Kei Shimakawa, So Doge, Masaki Michishita, Eri Tanabe, Tsuyoshi Tajima, Masato Kobayashi, Makoto Bonkobara, Masami Watanabe, Kazuhiko Ochiai, Yoshikazu Tanaka

    Gastrointestinal stromal tumors (GISTs) are mesenchymal tumors that develop in the gastrointestinal tract; KIT mutations are present in both canine and human GISTs. In this study, genomic DNA was extracted from formalin-fixed paraffin-embedded (FFPE) sections of 55 canine GIST cases, and mutation searches were performed for exons 8, 9, and 11. The results revealed novel mutations, A434T and F436S, in exon 8. In contrast to the A434T mutation without functional changes, the F436S mutant retained its dimerization ability, but lost its phosphorylation function and attenuated downstream Akt signaling, which is reflected in wound healing and migration activities. A comparison of the subcellular localization of WT KIT and the F436S mutant revealed no differences. In silico simulations indicated that the F436S mutation alters the structure of the near-membrane region and that its effects may extend to the transmembrane and intracellular domains compared to the WT. F436S is a point mutation that affects the entire molecule because co-mutation with the F436S mutation and the known autophosphorylation mutation reduces the autophosphorylation abilities.

  • Open Access

    Allele Frequencies and the Probability of Identity for 18 STR Loci Generated via the Canine GenotypesTM Panel 2.1 Kit in Golden Retriever, Miniature Dachshund, and Shiba Inu Groups for Forensic Applications

    by Fubuki Kunita, Chihiro Udagawa, Takeshi Inagaki, Hideto Suzuki, Makoto Bonkobara, Toshinori Omi

    Similarly to Europe and the United States, the need for the forensic DNA identification of dogs is increasing in Japan. Because few studies use commercial genotyping kits, we examine the effectiveness of individual DNA identification using the Canine Genotypes Panel 2.1 Kit on limited samples of dogs bred in Japan. We used Genomic DNA extracted from blood in non-related 50 Golden Retrievers, 50 Miniature Dachshunds, and 50 Shiba Inus bred in Japan. We investigated 18 canine STR markers (PEZ02, PEZ17, FH2017, FH2309, PEZ05, FH2001, FH2328, FH2004, FH2361, PEZ21, FH2054, FH3377, FH2107, FH2088, vWF.X, FH2010, PEZ16, and FH3313) and one sex-related marker (ZFX.Y) according to the manufacturer’s instructions. Allele frequency, He, Ho, p-value, PD, PE, PIC, and MP were calculated for each marker. Random Match probability based on 18 STR loci was subsequently estimated to be 3.257 × 10−16 in Golden Retrievers, 3.933 × 10−18 in Miniature Dachshunds, and 2.107 × 10−18 in the Shiba Inus breed. There are a few studies that have used this kit in Japan. The results suggest that the kit with 18 autosomal STR loci and one sex marker is effective in forensic applications.


  • Establishment of aBRAF V595E‐mutant canine prostate cancer cell line and the antitumor effects ofMEKinhibitors against canine prostate cancer

    by Masanori Kobayashi, Moe Onozawa, Shiho Watanabe, Tomokazu Nagashima, Kyoichi Tamura, Yoshiaki Kubo, Akiko Ikeda, Kazuhiko Ochiai, Masaki Michishita, Makoto Bonkobara, et al.

    Canine prostate cancer (cPCa) is a malignant neoplasm with no effective therapy. The BRAF V595E mutation, corresponding to the human BRAF V600E mutation, is found frequently in cPCa. Activating BRAF mutations are recognized as oncogenic drivers, and blockade of MAPK/ERK phosphorylation may be an effective therapeutic target against BRAF‐mutated tumours. The aim of this study was to establish a novel cPCa cell line and to clarify the antitumor effects of MEK inhibitors on cPCa in vitro and in vivo. We established the novel CHP‐2 cPCa cell line that was derived from the prostatic tissue of a cPCa patient. Sequencing of the canine BRAF gene in two cPCa cell lines revealed the presence of the BRAF V595E mutation. MEK inhibitors (trametinib, cobimetinib and mirdametinib) strongly suppressed cell proliferation in vitro, and trametinib showed the highest efficacy against cPCa cells with minimal cytotoxicity to non‐cancer COPK cells. Furthermore, we orally administered 0.3 or 1.0 mg/kg trametinib to CHP‐2 xenografted mice and examined its antitumor effects in vivo. Trametinib reduced tumour volume, decreased phosphorylated ERK levels, and lowered Ki‐67 expression in xenografts in a dose‐dependent manner. Although no clear adverse events were observed with administration, trametinib‐treated xenografts showed osteogenesis that was independent of dosage. Our results indicate that trametinib induces cell cycle arrest by inhibiting ERK activation, resulting in cPCa tumour regression in a dose‐dependent manner. MEK inhibitors, in addition to BRAF inhibitors, may be a targeted agent option for cPCa with the BRAF V595E mutation.


  • Open Access

    A feline case of multiple myeloma treated with bortezomib

    by Hiroyuki Tani, Ryo Miyamoto, Teruki Miyazaki, Shingo Oniki, Kyoichi Tamura, Makoto Bonkobara

    Background: Multiple myeloma (MM) is an uncommon neoplasm in cats. There is no established standard of treatment due to the rare occurrence of this disease in cats. Bortezomib is a proteasome inhibitor that serves as the first-line drug for MM in humans, but its effectiveness currently is unknown in feline MM. We present here the case report of a feline MM that exhibited a favorable response to bortezomib. Case presentation: The case was an 11-year-old non-castrated male domestic cat with light-chain MM presenting with clinical symptoms (anorexia, fatigue, and vomiting), mild azotemia, and pancytopenia. The cat failed on melphalan with prednisolone (MP), so bortezomib (Velcade) was initiated on Day 88. A total of 6 cycles of the treatment was performed, with each treatment cycle consisting of twice-weekly subcutaneous administration for 2 weeks followed by a 1-week rest. The dose of bortezomib was 0.7 mg/m2 for first week and 1.0 mg/m2 for second week in the first cycle. A dose of 0.7 mg/m2 was used for subsequent cycles. Prednisolone was used concomitantly in the first 2 cycles. Following treatment with bortezomib, clinical symptoms disappeared and a decrease in serum globulin and recovery of pancytopenia were noted. A monoclonal gammopathy, overproduction of serum immunoglobulin light chain, and Bence-Jones proteinuria that existed at diagnosis were undetectable on Day 123. A monoclonal gammopathy also was not detectable at the end of the bortezomib treatment (Day 213). Anorexia, fatigue, and marked bone marrow toxicity were experienced when bortezomib was administrated at a dose of 1.0 mg/m2, while no recognizable toxicity was observed at a dose of 0.7 mg/m2 throughout the treatment period. The case was placed on follow-up and there was no evidence of relapse as of Day 243. Conclusions: Bortezomib was effective and durable for the treatment of this case of feline MM after failure with MP. Bortezomib was well-tolerated in this cat at a dose of 0.7 mg/m2, but not at 1.0 mg/m2. Bortezomib appears to be a drug worthy of further study for the treatment of feline MM.


  • Molecular characterization of canine SHP2 mutants and anti‐tumour effect of SHP2 inhibitor, SHP099, in a xenograft mouse model of canine histiocytic sarcoma

    by Hiroyuki Tani, Ryo Miyamoto, Tomokazu Nagashima, Masaki Michishita, Kyoichi Tamura, Makoto Bonkobara

    Canine histiocytic sarcoma (HS) is an aggressive and highly metastatic neoplasm. Mutations in src homology 2 domain-containing phosphatase 2 (SHP2; encoded by PTPN11), which recently have been identified in canine HS tumour cells, could be attractive therapeutic targets for SHP099, an allosteric inhibitor of SHP2. Here, molecular characteristics of wild-type SHP2 and four SHP2 mutants (p.Ala72Gly, p.Glu76Gln, p.Glu76Ala and p.Gly503Val), including one that was newly identified in the present study, were investigated. Furthermore, in vivo effects of SHP099 on a HS cell line carrying SHP2 p.Glu76Ala were examined using a xenograft mouse model. While SHP2 Glu76 mutant cell lines and SHP2 wild-type/Gly503 mutant cell lines are highly susceptible and non-susceptible to SHP099, respectively, a cell line carrying the newly identified SHP2 p.Ala72Gly mutation exhibited moderate susceptibility to SHP099. Among recombinant wild-type protein and four mutant SHP2 proteins, three mutants (SHP2 p.Ala72Gly, p.Glu76Gln, p.Glu76Ala) were constitutively activated, while no activity was detected in wild-type SHP2 and SHP2 p.Gly503Val. Activities of these constitutively activated proteins were suppressed by SHP099; in particular, Glu76 mutants were highly sensitive. In the xenograft mouse model, SHP099 showed anti-tumour activity against a SHP2 p.Glu76Ala mutant cell line. Thus, there was heterogeneity in molecular characteristics among SHP2 mutants. SHP2 p.Glu76Ala and perhaps p.Glu76Gln, but not wild-type SHP2 or SHP2 p.Gly503Val, were considered to be oncogenic drivers targetable with SHP099 in canine HS. Further studies will be needed to elucidate the potential of SHP2 p.Ala72Gly as a therapeutic target of SHP099 in canine HS.


  • Open Access

    A canine case of malignant melanoma carrying a KIT c.1725_1733del mutation treated with toceranib: a case report and in vitro analysis

    by Hiroyuki Tani, Ryo Miyamoto, Syunya Noguchi, Sena Kurita, Tomokazu Nagashima, Masaki Michishita, Naoko Yayoshi, Kyoichi Tamura, Makoto Bonkobara

    Background: Canine malignant melanoma is highly aggressive and generally chemoresistant. Toceranib is a kinase inhibitor drug that inhibits several tyrosine kinases including the proto-oncogene receptor tyrosine kinase KIT. Although canine malignant melanoma cells often express KIT, a therapeutic effect for toceranib has yet to be reported for this tumor, with only a small number of patients studied to date. This is a case report of a dog with malignant melanoma that experienced a transient response to toceranib. Furthermore, the KIT expressed in the tumor of this case was examined using molecular analysis. Case presentation: A Shiba Inu dog presented with a gingival malignant melanoma extending into surrounding structures with metastasis to a submandibular lymph node. The dog was treated with toceranib (Palladia®; 2.6–2.9 mg/kg, orally, every other day) alone. Improvement of tumor-associated clinical signs (e.g., halitosis, tumor hemorrhage, trismus, and facial edema) with reduced size of the metastatic lymph node was observed on Day 15. The gingival tumor and associated masses in the masseter and pterygoid muscles decreased in size by Day 29 of treatment. Toceranib treatment was terminated on Day 43 due to disease progression and the dog died on Day 54. The tumor of this dog had a novel deletion mutation c.1725_1733del within KIT and the mutation caused ligand-independent phosphorylation of KIT, which was suppressed by toceranib. This mutation was considered to be an oncogenic driver mutation in the tumor of this dog, thereby explaining the anti-tumor activity of toceranib. Conclusions: This is the first report that presents a canine case of malignant melanoma that responded to toceranib therapy. KIT encoded by KIT harboring a mutation c.1725_1733del is a potential therapeutic target for toceranib in canine malignant melanoma. Further investigation of the KIT mutation status and toceranib therapy in canine malignant melanoma will need to be undertaken.